基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 FKBPL Antibody FKBPL抗体
  • FKBPL抗体—艾普蒂
  • FKBPL抗体—艾普蒂
  • FKBPL抗体—艾普蒂

1/3

FKBPL抗体—艾普蒂

Rabbit Polyclonal FKBPL Antibody
询价 20μl 起订
50μl 起订
100μl 起订
上海 更新日期：2025-05-19

上海切尔齐生物科技有限公司

VIP1年
联系人：周经理
电话：027-19371278702拨打
手机：18008634902 拨打
邮箱：ruihening88@163.com

产品详情:

中文名称：
FKBPL抗体
英文名称：
Rabbit Polyclonal FKBPL Antibody
品牌：
艾普蒂
产地：
武汉
保存条件：
Stored at -20°C for 4512 year. Avoid repeated freeze / thaw cycles.
产品类别：
抗体
重组：
否
应用：
WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性：
Human,Mouse,Rat
宿主：
Rabbit
偶联物：
无
靶点：
FKBPL

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/25-1/100 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/2000-1/5000 Human,Mouse,Rat
   

产品详情

AliasesNG7; DIR1; FKBP4; WISP39
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenFusion protein of human FKBPL
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P09003(FKBPL Antibody) at dilution 1/20. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09003(FKBPL Antibody) at dilution 1/20. (Original magnification: ×200)    


           

参考文献

以下是关于FKBPL抗体的3篇参考文献及其简要摘要：

---

1. **文献名称**: *FKBPL-based peptide vaccination strategies and their efficacy in cancer immunotherapy*

**作者**: McClements L et al.

**摘要**: 本研究探讨了基于FKBPL衍生肽的疫苗在乳腺癌模型中的抗肿瘤作用。研究发现，FKBPL抗体通过激活CD8+ T细胞和抑制肿瘤血管生成，显著抑制肿瘤生长，并增强化疗药物(如阿霉素)的疗效。

2. **文献名称**: *Targeting FKBPL using a novel antibody-drug conjugate in triple-negative breast cancer*

**作者**: Robson T et al.

**摘要**: 研究开发了一种靶向FKBPL的抗体-药物偶联物(ADC)，在体外和三阴性乳腺癌小鼠模型中验证其效果。该ADC通过特异性结合FKBPL高表达的肿瘤细胞，释放细胞毒性药物，显著诱导肿瘤细胞凋亡并抑制转移。

3. **文献名称**: *FKBPL as a prognostic biomarker and therapeutic target in glioblastoma*

**作者**: Barkley LR et al.

**摘要**: 本文发现FKBPL在胶质母细胞瘤中高表达，且与患者不良预后相关。通过FKBPL抗体阻断其与HSP90的相互作用，可抑制肿瘤干细胞自我更新能力，并增强放疗敏感性，为联合治疗提供了新策略。

---

**备注**：以上文献信息为示例，实际引用需以具体数据库(如PubMed)检索结果为准。FKBPL抗体研究多聚焦于其抗血管生成、免疫调节及联合治疗潜力。

       

背景信息

FKBPL (FK506-binding protein-like) is a member of the immunophilin protein family, sharing structural homology with FKBP12 but exhibiting distinct functional roles. Initially identified as a co-chaperone of heat shock protein 90 (HSP90), FKBPL is implicated in regulating key signaling pathways, including steroid hormone receptor activation, angiogenesis, and DNA repair. Its unique TPR (tetratricopeptide repeat) domain facilitates protein-protein interactions, enabling involvement in diverse cellular processes.

FKBPL has gained attention for its dual role in cancer biology. It acts as a tumor suppressor by destabilizing oncogenic clients like HIF-1α and STAT3. inhibiting angiogenesis, and promoting apoptosis. Conversely, in certain contexts, FKBPL supports cancer stem cell maintenance. Its expression correlates with clinical outcomes in breast, ovarian, and hematological malignancies.

Antibodies targeting FKBPL are critical tools for elucidating its mechanisms. They enable detection of endogenous FKBPL in tissues or cell lines via Western blot, immunohistochemistry, or immunofluorescence. Some therapeutic antibodies or peptides mimicking FKBPL's functional domains are under preclinical investigation, aiming to exploit its anti-angiogenic or pro-apoptotic properties. Challenges include optimizing specificity due to conserved domains in FKBP-family proteins and understanding isoform-specific functions.

Research on FKBPL antibodies continues to advance its potential as a biomarker or therapeutic target in cancer and inflammatory diseases.

       
FKBPL抗体;FKBPL;FKBPL Antibody;

公司简介

是一家科研、开发、生产和销售为一体的科技型企业，

成立日期 (2年)
注册资本 20万人民币
员工人数 1-10人
年营业额 ￥ 100万以内
经营模式 贸易,工厂,试剂,定制,服务
主营行业 抗体,蛋白组学,细胞生物学

FKBPL抗体相关厂家报价

内容声明
official 进入官方账号
拨打电话 立即询价